10.62
-0.19 (-1.76%)
| Previous Close | 10.81 |
| Open | 11.03 |
| Volume | 14,816 |
| Avg. Volume (3M) | 120,825 |
| Market Cap | 399,254,656 |
| Price / Earnings (TTM) | 6.32 |
| Price / Earnings (Forward) | 3.33 |
| Price / Sales | 7.34 |
| Price / Book | 1.21 |
| 52 Weeks Range | |
| Earnings Date | 7 May 2025 - 11 May 2025 |
| Profit Margin | 14.39% |
| Operating Margin (TTM) | -105.99% |
| Diluted EPS (TTM) | 0.580 |
| Quarterly Revenue Growth (YOY) | -65.20% |
| Total Debt/Equity (MRQ) | 13.66% |
| Current Ratio (MRQ) | 21.88 |
| Operating Cash Flow (TTM) | -54.55 M |
| Levered Free Cash Flow (TTM) | -65.48 M |
| Return on Assets (TTM) | 0.51% |
| Return on Equity (TTM) | 7.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Entrada Therapeutics, Inc. | Mixed | Mixed |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.75 |
|
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company’s Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 12.36% |
| % Held by Institutions | 80.37% |
| 52 Weeks Range | ||
| Median | 20.00 (88.32%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 11 Feb 2026 | 20.00 (88.32%) | Buy | 10.60 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Feb 2026 | Announcement | Entrada Therapeutics to Present at Upcoming Investor Conferences |
| 08 Jan 2026 | Announcement | Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases |
| 17 Dec 2025 | Announcement | Entrada Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 04 Dec 2025 | Announcement | Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |